[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-458444-105":59,"doc-detail-458444-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","impact-of-myocardial-perfusion-abnormalities-on-clinical-outcomes-in-patients-treated-with-percutaneous-coronary-intervention-for-chronic-total-occlusions-original-article","Impact of Myocardial Perfusion Abnormalities on Clinical Outcomes in Patients Treated with Percutaneous Coronary Intervention for Chronic Total Occlusions - Original Article","","Myocardial perfusion imaging (MPI) is used to assess ischaemia in chronic total occlusion (CTO) patients, yet its prognostic value after CTO percutaneous coronary intervention (CTO-PCI) remains unclear. This study evaluates clinical outcomes stratified by moderate–severe ischaemia on MPI before intervention, using a Western Danish Heart Registry cohort treated within 6 months and follow-up at 90 days and 5 years. Results show similar all-cause mortality and MACCE risk between groups, with a lower long-term angina hospitalization risk among those with moderate–severe ischaemia.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/impact-of-myocardial-perfusion-abnormalities-on-clinical-outcomes-in-patients-treated-with-percutaneous-coronary-intervention-for-chronic-total-occlusions-original-article/458444/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/impact-of-myocardial-perfusion-abnormalities-on-clinical-outcomes-in-patients-treated-with-percutaneous-coronary-intervention-for-chronic-total-occlusions-original-article/458444.png","ImageObject",300,407,{"name":92,"@type":93},"Rizky","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-30",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What is the study’s main question about myocardial perfusion abnormalities?","Question",{"text":112,"@type":113},"It assesses whether moderate–severe ischaemia on nuclear MPI before CTO-PCI influences clinical outcomes after the procedure.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was moderate–severe ischaemia defined for the analysis?",{"text":117,"@type":113},"Moderate–severe ischaemia was defined as at least 10% left ventricular involvement on MPI.",{"name":119,"@type":110,"acceptedAnswer":120},"Did moderate–severe ischaemia change overall survival or MACCE risk after CTO-PCI?",{"text":121,"@type":113},"No. All-cause mortality and the composite MACCE risk were comparable between patients with and without moderate–severe ischaemia at both 90 days and 5 years.",{"name":123,"@type":110,"acceptedAnswer":124},"What outcome differed between groups?",{"text":125,"@type":113},"Moderate–severe ischaemia was associated with a decreased 5-year risk of angina hospitalization, despite no differences in mortality or MACCE.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},458444,1791220775,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":143,"language":144,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":67,"update_tm":148,"read_time":41,"preview_page_count":4},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","European Heart Journal-Imaging Methods and Practice (2026) 4, qyaf137 [https://doi.org/10.1093/ehjimp/qyaf137](https://doi.org/10.1093/ehjimp/qyaf137)  \nORIGINAL ARTICLE  \nImpact of myocardial perfusion abnormalities on clinical outcomes in patients treated with percutaneous coronary intervention for chronic total occlusions  \nJesper Boes Henningsen1, Marc Meller Søndergaard1, Steen Hyldgaard Jørgensen1,  \nJacob Hartmann Søby  2, Morten Böttcher2, Laust Dupont Rasmussen1, Evald Høj Christiansen3, Emil Nielsen Holck4, Lisette Okkels Jensen5, Karsten Tange Veien5, Kirsten Bouchelouche6, Christian Torp Pedersen7, Kristian Hay Kragholm1, and Ashkan Eftekhari  1,*  \n1Department of Cardiology, Aalborg University Hospital, Hobrovej 18-20, Aalborg 9000, Denmark 2Department of Cardiology, Gødstrup Hospital, University Clinic for Cardiovascular Research, Herning, Denmark 3Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark  \n4Department of Internal Medicine and Cardiology, Horsens Regional Hospital, Horsens, Denmark 5Department of Cardiology, Odense University Hospital, Odense, Denmark  \n6Department of Nuclear Medicine, Aarhus University Hospital, Aarhus, Denmark 7Department of Cardiology and Clinical Investigation, North Zealand Hospital, Hillerød, Denmark  \nReceived 2 September 2025; accepted after revision 27 October 2025; online publish-ahead-of-print 8 January 2026  \nAbstract  \nIntroduction Myocardial perfusion imaging (MPI) is used to evaluate ischaemia in patients with chronic total occlusion (CTO), but its prognostic implications following percutaneous coronary intervention (PCI) of CTO remain uncertain.  \nPurpose To evaluate outcomes in patients treated with CTO-PCI stratified by moderate–severe ischaemia on MPI prior to  \nintervention.  \n. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  \nMethods and results  \nPatients from the Western Danish Heart Registry assessed by nuclear MPI and subsequently treated with CTO-PCI ≤ 6 months were included. Moderate–severe ischaemia was defined as ≥10% left ventricle involvement. Primary endpoints were all-cause mortality and a composite of major adverse cardio-and cerebrovascular events [MACCE; cardiovascular death, myocardial infarction (MI), stroke, and hospitalization for heart failure (HF) or angina pectoris]. Secondary endpoints included the individual MACCE components. Outcomes were compared between patients with and without moderate–severe ischaemia using multivariable Cox regression and competing risk regression at 90-day and 5-year follow-ups. Among 319 patients, 208 (65.2%) had moderate–severe ischaemia. All-cause mortality was similar between patients with and without moderate–severe ischaemia [adjusted hazard ratio (aHR) 1.12, 95% confidence interval (CI): 0.52–2.43], P = 0.77) . The estimated risk of MACCE was comparable between groups at 90 days [aHR 0.76 (0.38–1.55), P = 0.46] and 5 years [aHR 0.74 (0.45–1.20), P = 0.22]. No difference was found in MI [5 years: aHR 0.76 (0.26–2.22), P = 0.61] or hospitalization for HF [90 days: aHR 0.44 (0.16–1.21), P = 0.11]; 5 years: aHR 0.62 (0.30–1.30), P = 0.21] . Hospitalization for angina was similar at  \n* Corresponding author. E-mail: [asef@rn.dk](asef@rn.dk)  \n© The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.  \n90 ","cbCaioZp8luVkULz","https://ap.wps.com/l/cbCaioZp8luVkULz","pdf",1776415,12,"English","# Abstract\n# Introduction\n# Methods and results\n## Primary endpoints\n## Secondary endpoints\n# Conclusion\n# Graphical Abstract\n# Keywords","[{\"question\":\"What is the study’s main question about myocardial perfusion abnormalities?\",\"answer\":\"It assesses whether moderate–severe ischaemia on nuclear MPI before CTO-PCI influences clinical outcomes after the procedure.\"},{\"question\":\"How was moderate–severe ischaemia defined for the analysis?\",\"answer\":\"Moderate–severe ischaemia was defined as at least 10% left ventricular involvement on MPI.\"},{\"question\":\"Did moderate–severe ischaemia change overall survival or MACCE risk after CTO-PCI?\",\"answer\":\"No. All-cause mortality and the composite MACCE risk were comparable between patients with and without moderate–severe ischaemia at both 90 days and 5 years.\"},{\"question\":\"What outcome differed between groups?\",\"answer\":\"Moderate–severe ischaemia was associated with a decreased 5-year risk of angina hospitalization, despite no differences in mortality or MACCE.\"}]","Impact of Myocardial Perfusion Abnormalities on Clinical Outcomes in Patients Treated with Percutaneous Coronary Intervention for Chronic Total Occlusions - Original Article | PDF",1790753154]